Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13107102 | 0.86 | NAMPT (0.55) | NAMPT | |
| SCHEMBL13349918 | 0.83 | F10 (0.49) | MAPTRAB9AACACA | |
| SCHEMBL13097136 | 0.83 | ALDH1A1 (0.54) | MAPTRAB9ANAMPT | |
| SCHEMBL13106516 | 0.82 | HRH3 (0.44) | MAPTPIK3CDPIK3CAACACAHRH3 | |
| SCHEMBL13097137 | 0.81 | NAMPT (0.48) | RAB9APIK3CDPIK3CANAMPTHRH3 | |
| SCHEMBL13106654 | 0.80 | HRH3 (0.45) | MAPTPIK3CDPIK3CAACACAHRH3 | |
| SCHEMBL13107104 | 0.79 | PDE4D (0.54) | HRH3 | |
| SCHEMBL13349840 | 0.78 | NAMPT (0.46) | RAB9APIK3CDPIK3CANAMPTHRH3 | |
| SCHEMBL13107291 | 0.77 | POLB (0.53) | PIK3CDHRH2HRH1 | |
| SCHEMBL21814291 | 0.76 | NAMPT (0.54) | MAPTPIK3CDPIK3CANAMPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | MAPT 4661/4885RAB9A 2422/4885PIK3CD 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.